GSK plc or Takeda Pharmaceutical Company Limited: Who Manages SG&A Costs Better?

GSK vs. Takeda: A Decade of SG&A Management

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Takeda Pharmaceutical Company Limited have shown contrasting approaches. From 2014 to 2023, GSK's SG&A expenses fluctuated modestly, peaking in 2020 at approximately $11.5 billion before dropping to around $9.4 billion in 2023. In contrast, Takeda's expenses soared, starting at $612 billion in 2014 and reaching over $1 trillion by 2023, marking a staggering 72% increase.

This divergence highlights different strategic priorities. GSK's relatively stable expenses suggest a focus on cost control, while Takeda's rising costs may reflect aggressive expansion or investment in innovation. Notably, data for GSK in 2024 is missing, leaving room for speculation on future trends. As these giants navigate the evolving pharmaceutical landscape, their SG&A strategies will be pivotal in shaping their competitive edge.